<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">660</journal-id><journal-id journal-id-type="pmc-domain">jco</journal-id><journal-id journal-id-type="publisher-id">JCO</journal-id><journal-title-group><journal-title>Journal of Clinical Oncology</journal-title></journal-title-group><issn pub-type="ppub">0732-183X</issn><issn pub-type="epub">1527-7755</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10414726</article-id><article-id pub-id-type="pmcid-ver">PMC10414726.1</article-id><article-id pub-id-type="pmcaid">10414726</article-id><article-id pub-id-type="pmcaiid">10414726</article-id><article-id pub-id-type="pmid">36626695</article-id><article-id pub-id-type="doi">10.1200/JCO.22.01413</article-id><article-id pub-id-type="publisher-id">JCO.22.01413</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>ORIGINAL REPORTS</subject><subj-group><subject>Health Services and Outcomes</subject></subj-group></subj-group></article-categories><title-group><article-title>Racial and Ethnic Disparities in Opioid Access and Urine Drug Screening Among Older Patients With Poor-Prognosis Cancer Near the End of Life</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7502-8081</contrib-id><name name-style="western"><surname>Enzinger</surname><given-names initials="AC">Andrea C.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghosh</surname><given-names initials="K">Kaushik</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8274-4681</contrib-id><name name-style="western"><surname>Keating</surname><given-names initials="NL">Nancy L.</given-names></name><degrees>MD, MPH</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4949-8917</contrib-id><name name-style="western"><surname>Cutler</surname><given-names initials="DM">David M.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6782-6382</contrib-id><name name-style="western"><surname>Clark</surname><given-names initials="CR">Cheryl R.</given-names></name><degrees>MD, ScD</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7814-1773</contrib-id><name name-style="western"><surname>Florez</surname><given-names initials="N">Narjust</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5055-8473</contrib-id><name name-style="western"><surname>Landrum</surname><given-names initials="MB">Mary Beth</given-names></name><degrees>PhD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9776-7114</contrib-id><name name-style="western"><surname>Wright</surname><given-names initials="AA">Alexi A.</given-names></name><degrees>MD, MPH</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA</aff><aff id="aff2"><label><sup>2</sup></label>New England Bureau of Economic Research, Cambridge, MA</aff><aff id="aff3"><label><sup>3</sup></label>Department of Healthcare Policy, Harvard Medical School, Boston, MA</aff><aff id="aff4"><label><sup>4</sup></label>Division of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital, Boston, MA</aff><aff id="aff5"><label><sup>5</sup></label>Department of Economics, Harvard University, Boston, MA</aff><aff id="aff6"><label><sup>6</sup></label>Department of Health Policy and Management, Harvard T.H. Chan School of Public Health (DMC), Boston, MA</aff></contrib-group><author-notes><corresp id="cor1">Andrea C. Enzinger, MD, Dana-Farber Cancer Institute, Dana Building 1103, 450 Brookline Ave, Boston, MA 02115; e-mail: <email>andrea_enzinger@dfci.harvard.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><day>10</day><month>5</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>1</month><year>2023</year></pub-date><volume>41</volume><issue>14</issue><issue-id pub-id-type="pmc-issue-id">442898</issue-id><fpage>2511</fpage><lpage>2522</lpage><history><date date-type="received"><day>22</day><month>6</month><year>2022</year></date><date date-type="rev-recd"><day>16</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>10</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-10 00:25:17.400"><day>10</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by American Society of Clinical Oncology</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>American Society of Clinical Oncology</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jco-41-2511.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jco-41-2511.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="companion" xml:lang="en" journal-id="J Clin Oncol" journal-id-type="nlm-ta" ext-link-type="pubmed" xlink:href="36827632"><article-title>Examining Racial and Ethnic Inequities in Opioid Prescribing and Risk Screening Among Patients With Advanced Cancer.</article-title><date><day>24</day><month>2</month><year>2023</year></date><fpage>JCO2202879</fpage><lpage>JCO2202879</lpage><source>J Clin Oncol</source><pub-id pub-id-type="doi">10.1200/JCO.22.02879</pub-id><pub-id pub-id-type="pmid">36827632</pub-id></related-article><abstract><title>PURPOSE</title><p>To characterize racial and ethnic disparities and trends in opioid access and urine drug screening (UDS) among patients dying of cancer, and to explore potential mechanisms.</p><sec><title>METHODS</title><p>Among 318,549 non-Hispanic White (White), Black, and Hispanic Medicare decedents older than 65 years with poor-prognosis cancers, we examined 2007-2019 trends in opioid prescription fills and potency (morphine milligram equivalents [MMEs] per day [MMEDs]) near the end of life (EOL), defined as 30 days before death or hospice enrollment. We estimated the effects of race and ethnicity on opioid access, controlling for demographic and clinical factors. Models were further adjusted for socioeconomic factors including dual-eligibility status, community-level deprivation, and rurality. We similarly explored disparities in UDS.</p></sec><sec><title>RESULTS</title><p>Between 2007 and 2019, White, Black, and Hispanic decedents experienced steady declines in EOL opioid access and rapid expansion of UDS. Compared with White patients, Black and Hispanic patients were less likely to receive any opioid (Black, &#8211;4.3 percentage points, 95% CI, &#8211;4.8 to &#8211;3.6; Hispanic, &#8211;3.6 percentage points, 95% CI, &#8211;4.4 to &#8211;2.9) and long-acting opioids (Black, &#8211;3.1 percentage points, 95% CI, &#8211;3.6 to &#8211;2.8; Hispanic, &#8211;2.2 percentage points, 95% CI, &#8211;2.7 to &#8211;1.7). They also received lower daily doses (Black, &#8211;10.5 MMED, 95% CI, &#8211;12.8 to &#8211;8.2; Hispanic, &#8211;9.1 MMED, 95% CI, &#8211;12.1 to &#8211;6.1) and lower total doses (Black, &#8211;210 MMEs, 95% CI, &#8211;293 to &#8211;207; Hispanic, &#8211;179 MMEs, 95% CI, &#8211;217 to &#8211;142); Black patients were also more likely to undergo UDS (0.5 percentage points; 95% CI, 0.3 to 0.8). Disparities in EOL opioid access and UDS disproportionately affected Black men. Adjustment for socioeconomic factors did not attenuate the EOL opioid access disparities.</p></sec><sec><title>CONCLUSION</title><p>There are substantial and persistent racial and ethnic inequities in opioid access among older patients dying of cancer, which are not mediated by socioeconomic variables.</p></sec></abstract><counts><fig-count count="7"/><table-count count="3"/><equation-count count="0"/><ref-count count="66"/><page-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>